Aphe, care taker of Abino (pseudonym), 20 years old, MDR-TB patient gives her anti-TB medicines. Abino says, “I live in a big family of 10 members. Yet no one cares for me or talks to me, except my sister in law, Aphe. When I could not get up, she brought me food and water. She gives me the medicines on time every day.” Photograph by Siddharth Singh
Report |

DR-TB Drugs Under the Microscope, 3rd Edition

TUBERCULOSIS
MSF_TB_Report_UTM3rdEdition-2013.pdf
ReportCover-DRTBDrugsUnderTheMicroscope-2013-3rdEditionn
Photograph by Siddharth Singh

This report focuses on just some of the many factors that hamper the scaling up of DR-TB treatment – the limited availability and high cost of quality-assured medicines for resistant strains of the disease, owing to an insecure market and insufficient demand; and the research questions that remain unsolved with existing medicines.

Also, as the R&D pipeline prepares to deliver the first new compounds for TB in close to half a century, the report provides an initial assessment of the approaches to be taken in order to radically transform our ability to respond to this plague.

Additional publications in the DR-TB Drugs Under the Microscope report series are available here.

Learn more about MSF’s work to improve access to lifesaving TB treatment.

DR-TB Drugs Under the Microscope, 3rd Edition